Jason T. Chittenden
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jason T. Chittenden has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Jim E. Riviere
Institute of Computational Comparative Medicine, Mosier P200A, Kansas State University, Manhattan, KS, 66506-5802, USA
2 shared publications- A. Thomas DiCioccio
Regeneron Pharmaceuticals, Inc. Tarrytown New York USA
1 shared publication James D. Brooks
Center for Chemical Toxicology Research and Pharmacokinetics, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina 27607
1 shared publication- Jim Riviere
DATA Consortium, Kansas State University Olathe, Olathe, KS 66061, USA
1 shared publication - Joachim Höchel
Bayer AG Berlin Germany
1 shared publication - Joannellyn Chiu
Regeneron Pharmaceuticals, Inc Tarrytown New York USA
1 shared publication
Latest Publications
- Open Access
- 30 June 2026
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (7) , e70287
Integrated Population Pharmacokinetic Analysis of Intravitreal Aflibercept Drug Products
Neovascular age‐related macular degeneration (nAMD) and diabetic macular edema (DME) can cause substantial vision loss. The 2‐mg drug product of aflibercept (AFL‐2)—an anti‐vascular endothelial growth factor agent—has established efficacy and safety in both diseases. In pivotal trials, a high‐dose drug product (AFL‐HD) using a formulation distinct from AFL‐2 and delivering 8‐mg aflibercept every 12 or 16 weeks (following initial monthly dosing) provided visual gains non‐inferior to AFL‐2 administered every 8 weeks (following initial monthly dosing) and comparable safety with fewer injections over 96 weeks. Free and bound aflibercept concentrations in plasma from 2744 participants in 16 clinical trials where aflibercept was administered intravitreally, subcutaneously, or intravenously were analyzed by population pharmacokinetic modeling. A semi‐mechanistic model described the release of free aflibercept from the eye and its target‐mediated elimination from plasma. The evaluated covariates (weight, age, sex, albumin, disease, racial classification, Japanese origin, renal and hepatic functions) resulted in only small numerical differences in systemic exposure. Ocular clearance ( Q E ; characterizing the bidirectional transfer of free aflibercept between the eye and central compartment) was comparable across both diseases after adjusting for an age‐dependent decrease. The change in drug product, and not just the dose increase, was responsible for a 39.4% slower Q E and extended exposure in the ocular space for AFL‐HD versus AFL‐2. The median ocular concentrations of free aflibercept predicted at the end of the 8‐week dosing interval for AFL‐2 were typically reached 14 weeks after AFL‐HD injections, versus 9–9.5 weeks if Q E was identical for both drug products.
- 30 June 2026
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (7) , e70287
Open AccessIntegrated Population Pharmacokinetic Analysis of Intravitreal Aflibercept Drug Products
Neovascular age‐related macular degeneration (nAMD) and diabetic macular edema (DME) can cause substantial vision loss. The 2‐mg drug product of aflibercept (AFL‐2)—an anti‐vascular endothelial growth factor agent—has established efficacy and safety in both diseases. In pivotal trials, a high‐dose drug product (AFL‐HD) using a formulation distinct from AFL‐2 and delivering 8‐mg aflibercept every 12 or 16 weeks (following initial monthly dosing) provided visual gains non‐inferior to AFL‐2 administered every 8 weeks (following initial monthly dosing) and comparable safety with fewer injections over 96 weeks. Free and bound aflibercept concentrations in plasma from 2744 participants in 16 clinical trials where aflibercept was administered intravitreally, subcutaneously, or intravenously were analyzed by population pharmacokinetic modeling. A semi‐mechanistic model described the release of free aflibercept from the eye and its target‐mediated elimination from plasma. The evaluated covariates (weight, age, sex, albumin, disease, racial classification, Japanese origin, renal and hepatic functions) resulted in only small numerical differences in systemic exposure. Ocular clearance ( Q E ; characterizing the bidirectional transfer of free aflibercept between the eye and central compartment) was comparable across both diseases after adjusting for an age‐dependent decrease. The change in drug product, and not just the dose increase, was responsible for a 39.4% slower Q E and extended exposure in the ocular space for AFL‐HD versus AFL‐2. The median ocular concentrations of free aflibercept predicted at the end of the 8‐week dosing interval for AFL‐2 were typically reached 14 weeks after AFL‐HD injections, versus 9–9.5 weeks if Q E was identical for both drug products.
- 1 June 2016
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 37 (7) , 387-396
Assessment of penetrant and vehicle mixture properties on transdermal permeability using a mixed effect pharmacokinetic model ofex vivoporcine skin
The accurate prediction of the rate and extent of transdermal absorption from topical exposure to chemical mixtures would be beneficial in risk assessment and drug delivery applications. The isolated perfused porcine skin flap (IPPSF) has been used as anex vivomodel for assessing transdermal absorption from topical exposures. A mixed effect, pharmacokinetic tissue model was used to model finite dose, transdermal, absorption data from IPPSF experiments for 12 penetrants dosed in up to 10 different vehicles. The model was able to identify permeability constant, while accounting for between and within unit variability, across the entire data set. This approach provides a platform for exploring the relationship between covariates (chemical descriptors and functions thereof) and the model parameters. Successive models were employed that reduced the overall variability in the parameter estimate by modeling the parameters as functions of the covariates. Logkpwas initially modeled as a function of LogPand MW of the pure penetrant (adjustedr2 = 0.48). The addition of mixture factors to account for the different dosing vehicles further improved the relationship: tor2 = 0.56 with Connolly molecular area (CMA) andr2 = 0.78 with the further addition of total polar surface area difference (TPSAd). The pharmacokinetic model and quantitative structure property relationship (QSPR) developed for the IPPSF may be relevant to clinical transdermal formulation development. Copyright © 2016 John Wiley & Sons, Ltd.
- 1 June 2016
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 37 (7) , 387-396
Assessment of penetrant and vehicle mixture properties on transdermal permeability using a mixed effect pharmacokinetic model ofex vivoporcine skin
The accurate prediction of the rate and extent of transdermal absorption from topical exposure to chemical mixtures would be beneficial in risk assessment and drug delivery applications. The isolated perfused porcine skin flap (IPPSF) has been used as anex vivomodel for assessing transdermal absorption from topical exposures. A mixed effect, pharmacokinetic tissue model was used to model finite dose, transdermal, absorption data from IPPSF experiments for 12 penetrants dosed in up to 10 different vehicles. The model was able to identify permeability constant, while accounting for between and within unit variability, across the entire data set. This approach provides a platform for exploring the relationship between covariates (chemical descriptors and functions thereof) and the model parameters. Successive models were employed that reduced the overall variability in the parameter estimate by modeling the parameters as functions of the covariates. Logkpwas initially modeled as a function of LogPand MW of the pure penetrant (adjustedr2 = 0.48). The addition of mixture factors to account for the different dosing vehicles further improved the relationship: tor2 = 0.56 with Connolly molecular area (CMA) andr2 = 0.78 with the further addition of total polar surface area difference (TPSAd). The pharmacokinetic model and quantitative structure property relationship (QSPR) developed for the IPPSF may be relevant to clinical transdermal formulation development. Copyright © 2016 John Wiley & Sons, Ltd.
- 1 November 2015
- Published by Elsevier in Journal of Controlled Release
- Vol. 217, 74-81
Quantification of vehicle mixture effects on in vitro transdermal chemical flux using a random process diffusion model
- 1 November 2015
- Published by Elsevier in Journal of Controlled Release
- Vol. 217, 74-81
Quantification of vehicle mixture effects on in vitro transdermal chemical flux using a random process diffusion model
- 1 March 2014
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 103 (3) , 1002-1012
Development of a Mixed-Effect Pharmacokinetic Model for Vehicle Modulated In Vitro Transdermal Flux of Topically Applied Penetrants
- 1 March 2014
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 103 (3) , 1002-1012
Development of a Mixed-Effect Pharmacokinetic Model for Vehicle Modulated In Vitro Transdermal Flux of Topically Applied Penetrants
- Open Access
- 24 October 2012
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 34 (5) , 262-277
Analysis of level A in vitro–in vivo correlations for an extended‐release formulation with limited bioavailability
A two‐stage, numerical deconvolution approach was employed to develop level A in vitro–in vivo correlations using data for three formulations of an extended‐release oral dosage form. The in vitro dissolution data for all formulations exhibited near‐complete dissolution within the time frame of the test. The pharmacokinetic concentration–time profiles for 16 subjects in a cross‐over study demonstrated notably limited bioavailability for the slowest formulation. These data were used as the basis for the IVIVC model development. Two models were identified that satisfied the nominal requirements for a conclusive internal predictability of the IVIVC, provided that all three formulations were used as internal datasets. These were a simple linear model with absorption cut‐off and a piecewise‐linear variable absorption scale model. A subsequent cross‐validation of the models' robustness indicated that neither model predicted satisfactorily the pharmacokinetic characteristics of all formulations in a conclusive manner. The piecewise‐linear variable absorption scale model provided the most accurate results, particularly with respect to the prediction of the slowest formulation's pharmacokinetic metrics. But this latter model also involved additional free parameters compared with the simple linear model with absorption cut‐off. It is argued that more complex IVIVC models with extra parameterization require comprehensive validation to ascertain the accuracy and robustness of the model. In order to achieve this, it is necessary to ensure a complete suite of supporting datasets for internal and external validation, irrespective of the mathematical approach used subsequently to develop the IVIVC. Copyright © 2013 John Wiley & Sons, Ltd.
- 24 October 2012
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 34 (5) , 262-277
Open AccessAnalysis of level A in vitro–in vivo correlations for an extended‐release formulation with limited bioavailability
A two‐stage, numerical deconvolution approach was employed to develop level A in vitro–in vivo correlations using data for three formulations of an extended‐release oral dosage form. The in vitro dissolution data for all formulations exhibited near‐complete dissolution within the time frame of the test. The pharmacokinetic concentration–time profiles for 16 subjects in a cross‐over study demonstrated notably limited bioavailability for the slowest formulation. These data were used as the basis for the IVIVC model development. Two models were identified that satisfied the nominal requirements for a conclusive internal predictability of the IVIVC, provided that all three formulations were used as internal datasets. These were a simple linear model with absorption cut‐off and a piecewise‐linear variable absorption scale model. A subsequent cross‐validation of the models' robustness indicated that neither model predicted satisfactorily the pharmacokinetic characteristics of all formulations in a conclusive manner. The piecewise‐linear variable absorption scale model provided the most accurate results, particularly with respect to the prediction of the slowest formulation's pharmacokinetic metrics. But this latter model also involved additional free parameters compared with the simple linear model with absorption cut‐off. It is argued that more complex IVIVC models with extra parameterization require comprehensive validation to ascertain the accuracy and robustness of the model. In order to achieve this, it is necessary to ensure a complete suite of supporting datasets for internal and external validation, irrespective of the mathematical approach used subsequently to develop the IVIVC. Copyright © 2013 John Wiley & Sons, Ltd.